{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:09:57Z","timestamp":1768439397466,"version":"3.49.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40120-025-00872-1","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T09:54:44Z","timestamp":1765965284000},"page":"401-420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Dawn C.","family":"Buse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Urman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruti J.","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah C.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice S.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra B.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Bensink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2775-3275","authenticated-orcid":false,"given":"Alice R.","family":"Pressman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"872_CR1","unstructured":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204\u201322."},{"issue":"5","key":"872_CR2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343\u20139.","journal-title":"Neurology"},{"issue":"3","key":"872_CR3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0333102410381145","volume":"31","author":"AM Blumenfeld","year":"2011","unstructured":"Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3):301\u201315.","journal-title":"Cephalalgia"},{"issue":"7","key":"872_CR4","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/0333102411398400","volume":"31","author":"M Lant\u00e9ri-Minet","year":"2011","unstructured":"Lant\u00e9ri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 2011;31(7):837\u201350.","journal-title":"Cephalalgia"},{"issue":"1","key":"872_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"American Headache Society","year":"2019","unstructured":"American Headache Society. The American Headache Society Position Statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1\u201318.","journal-title":"Headache"},{"issue":"7","key":"872_CR6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021\u201339.","journal-title":"Headache"},{"issue":"4","key":"872_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64(4):333\u201341.","journal-title":"Headache"},{"issue":"1","key":"872_CR8","first-page":"22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20(1):22\u201333.","journal-title":"J Manag Care Pharm"},{"issue":"5","key":"872_CR9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37(5):470\u201385.","journal-title":"Cephalalgia"},{"issue":"6","key":"872_CR10","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478\u201388.","journal-title":"Cephalalgia"},{"issue":"12","key":"872_CR11","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1080\/14712598.2019.1671350","volume":"19","author":"B Raffaelli","year":"2019","unstructured":"Raffaelli B, Neeb L, Reuter U. Monoclonal antibodies for the prevention of migraine. Expert Opin Biol Ther. 2019;19(12):1307\u201317.","journal-title":"Expert Opin Biol Ther"},{"key":"872_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/B978-0-12-823357-3.00033-1","volume":"199","author":"S Younis","year":"2024","unstructured":"Younis S, Latysheva NV, Danilov AB, Ashina M. CGRP receptor antagonists (gepants). Handb Clin Neurol. 2024;199:51\u201366.","journal-title":"Handb Clin Neurol"},{"issue":"2","key":"872_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.410280213","volume":"28","author":"PJ Goadsby","year":"1990","unstructured":"Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183\u20137.","journal-title":"Ann Neurol"},{"key":"872_CR14","unstructured":"Aimovig (Erenumab-aooe subcutaneous injection) Prescribing Information. Thousand Oaks: Amgen Inc.; 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761077s009lbl.pdf."},{"key":"872_CR15","unstructured":"Ajovy\u2122 (fremanezumab-vfrm subcutaneous injection) Prescribing Information. North Wales: TEVA Pharmaceuticals; 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761089s013lbl.pdf."},{"key":"872_CR16","unstructured":"Emgality\u2122 (galcanezumab-gnlm subcutaneous injection) Prescribing Information. Indianapolis: Eli Lilly and Company; 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761063s003lbl.pdf."},{"key":"872_CR17","unstructured":"VYEPTI\u2122 (eptinezumab-jjmr intravenous injection) Prescribing Information. Bothell: Lundbeck Seattle BioPharmaceuticals; 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761119s006lbl.pdf."},{"issue":"1","key":"872_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20142022 update. J Headache Pain. 2022;23(1):67.","journal-title":"J Headache Pain"},{"issue":"3","key":"872_CR19","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/head.14033","volume":"61","author":"AR Pressman","year":"2021","unstructured":"Pressman AR, Buse DC, Jacobson AS, Vaidya SJ, Scott AB, Chia VM, et al. The migraine signature study: methods and baseline results. Headache. 2021;61(3):462\u201384.","journal-title":"Headache"},{"issue":"2","key":"872_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"issue":"7","key":"872_CR21","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1046\/j.1526-4610.2001.041007638.x","volume":"41","author":"RB Lipton","year":"2001","unstructured":"Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache. 2001;41(7):638\u201345.","journal-title":"Headache"},{"key":"872_CR22","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211.","DOI":"10.1177\/0333102417738202"},{"issue":"1","key":"872_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0304-3959(00)00305-5","volume":"88","author":"WF Stewart","year":"2000","unstructured":"Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000;88(1):41\u201352.","journal-title":"Pain"},{"issue":"3","key":"872_CR24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MLR.0b013e318160d093","volume":"46","author":"B L\u00f6we","year":"2008","unstructured":"L\u00f6we B, Decker O, M\u00fcller S, Br\u00e4hler E, Schellberg D, Herzog W, et al. Validation and standardization of the generalized anxiety disorder screener (GAD-7) in the general population. Med Care. 2008;46(3):266\u201374.","journal-title":"Med Care"},{"issue":"9","key":"872_CR25","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606\u201313.","journal-title":"J Gen Intern Med"},{"issue":"1-3","key":"872_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jad.2008.06.026","volume":"114","author":"K Kroenke","year":"2009","unstructured":"Kroenke K, Strine TW, Spitzer RL, Williams JB, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114(1\u20133):163\u201373.","journal-title":"J Affect Disord"},{"issue":"5","key":"872_CR27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S0025-6196(11)60561-2","volume":"84","author":"DC Buse","year":"2009","unstructured":"Buse DC, Rupnow MF, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009;84(5):422\u201335.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"872_CR28","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/head.13028","volume":"57","author":"RB Lipton","year":"2017","unstructured":"Lipton RB, Buse DC, Adams AM, Varon SF, Fanning KM, Reed ML. Family impact of migraine: development of the impact of migraine on partners and adolescent children (IMPAC) scale. Headache. 2017;57(4):570\u201385.","journal-title":"Headache"},{"issue":"7","key":"872_CR29","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1046\/j.1526-4610.2000.00086.x","volume":"40","author":"DL Patrick","year":"2000","unstructured":"Patrick DL, Hurst BC, Hughes J. Further development and testing of the migraine-specific quality of life (MSQOL) measure. Headache. 2000;40(7):550\u201360.","journal-title":"Headache"},{"issue":"5","key":"872_CR30","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/head.14709","volume":"64","author":"F Cohen","year":"2024","unstructured":"Cohen F, Brooks CV, Sun D, Buse DC, Reed ML, Fanning KM, et al. Prevalence and burden of migraine in the United States: a systematic review. Headache. 2024;64(5):516\u201332.","journal-title":"Headache"},{"key":"872_CR31","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.mayocp.2016.02.013","volume":"91","author":"DC Buse","year":"2016","unstructured":"Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Manack Adams A, et al. Impact of migraine on the family: perspectives of people with migraine and their spouse\/domestic partner in the CaMEO study. Mayo Clin Proc. 2016;91:596\u2013611.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"872_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/03331024231180611","volume":"43","author":"AM Adams","year":"2023","unstructured":"Adams AM, Buse DC, Leroux E, Lanteri-Minet M, Sakai F, Matharu MS, et al. Chronic Migraine Epidemiology and Outcomes-International (CaMEO-I) study: methods and multi-country baseline findings for diagnosis rates and care. Cephalalgia. 2023;43(6):1\u201313.","journal-title":"Cephalalgia"},{"issue":"1","key":"872_CR33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s10194-025-02146-5","volume":"26","author":"P Barbanti","year":"2025","unstructured":"Barbanti P, Fiorentini G, Camarda C, Autunno M, Pistoia F, Aurilia C, et al. Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE). J Headache Pain. 2025;26(1):199.","journal-title":"J Headache Pain"},{"issue":"1","key":"872_CR34","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s10194-025-02067-3","volume":"26","author":"F Gabrielli","year":"2025","unstructured":"Gabrielli F, Zuel M, Magaud C, Sickout-Arondo S, Pereira B, Dassa J, et al. Validation of an 8-item self-administered questionnaire for assessing migraine-related sensory hypersensitivities (MHQ-8). J Headache Pain. 2025;26(1):128.","journal-title":"J Headache Pain"},{"key":"872_CR35","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2147\/PPA.S346660","volume":"16","author":"OJ Varnado","year":"2022","unstructured":"Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R. Treatment patterns for calcitonin gene-related peptide monoclonal antibodies including galcanezumab versus conventional preventive treatments for migraine: a retrospective US claims study. Patient Prefer Adherence. 2022;16:821\u201339.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"872_CR36","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s40122-021-00319-z","volume":"10","author":"D Chandler","year":"2021","unstructured":"Chandler D, Szekely C, Aggarwal S, Cyprien L, Bensink M. Migraine characteristics, comorbidities, healthcare resource utilization, and associated costs of early users of erenumab in the USA: a retrospective cohort study using administrative claims data. Pain Ther. 2021;10(2):1551\u201366.","journal-title":"Pain Ther"},{"issue":"5","key":"872_CR37","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s40122-024-00644-z","volume":"13","author":"R Urman","year":"2024","unstructured":"Urman R, Princic N, Vuvu F, Patel LB, Oh S, Chandler D, et al. Changes in use of migraine medications, healthcare resource utilization, and associated direct costs over 12 months following initiation of erenumab: a US retrospective real-world analysis. Pain Ther. 2024;13(5):1299\u2013313.","journal-title":"Pain Ther"},{"key":"872_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/head.14820","author":"JK Multani","year":"2024","unstructured":"Multani JK, Urman R, Park AS, Gill K, Vuvu F, Sun K, et al. Changes in use of acute and preventive medications for migraine after erenumab initiation over 12\u00a0months: a United States retrospective cohort study. Headache. 2024. https:\/\/doi.org\/10.1111\/head.14820.","journal-title":"Headache"},{"issue":"4","key":"872_CR39","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/head.14068","volume":"61","author":"DM Hines","year":"2021","unstructured":"Hines DM, Shah S, Multani JK, Wade RL, Buse DC, Bensink M. Erenumab patient characteristics, medication adherence, and treatment patterns in the United States. Headache. 2021;61(4):590\u2013602.","journal-title":"Headache"},{"issue":"1","key":"872_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/head.14218","volume":"62","author":"J Gladstone","year":"2022","unstructured":"Gladstone J, Chhibber S, Minhas J, Neish CS, Power GS, Lan Z, et al. Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: retrospective real-world study. Headache. 2022;62(1):78\u201388.","journal-title":"Headache"},{"key":"872_CR41","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.2147\/PPA.S435782","volume":"17","author":"OJ Varnado","year":"2023","unstructured":"Varnado OJ, Gulati T, Wheeler A, Hoyt M. Treatment patterns, healthcare resource utilization, and direct costs among patients initiating concomitant use of a calcitonin gene-related peptide monoclonal antibody (CGRP mAb) and novel acute medication in the United States. Patient Prefer Adherence. 2023;17:3449\u201359.","journal-title":"Patient Prefer Adherence"},{"key":"872_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14030734","author":"MK Kang","year":"2025","unstructured":"Kang MK, Sohn JH, Cha MJ, Kim YH, Hong Y, Im HJ, et al. One-year compliance after calcitonin gene-related peptide monoclonal antibody therapy for migraine patients in a real-world setting: a multicenter cross-sectional study. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14030734.","journal-title":"J Clin Med"},{"issue":"3","key":"872_CR43","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s40122-024-00583-9","volume":"13","author":"DC Buse","year":"2024","unstructured":"Buse DC, Krasenbaum LJ, Seminerio MJ, Packnett ER, Carr K, Ortega M, et al. Real-world impact of fremanezumab on migraine-related health care resource utilization in patients with comorbidities, acute medication overuse, and\/or unsatisfactory prior migraine preventive response. Pain Ther. 2024;13(3):511\u201332.","journal-title":"Pain Ther"},{"issue":"1","key":"872_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01636-8","volume":"24","author":"Lt Charleston","year":"2023","unstructured":"Charleston Lt, Talon B, Sullivan C, Anderson C, Kymes S, Regnier SA, et al. Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study. J Headache Pain. 2023;24(1):101.","journal-title":"J Headache Pain"},{"issue":"2","key":"872_CR45","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1007\/s12325-024-03072-9","volume":"42","author":"G Kim","year":"2025","unstructured":"Kim G, Hoyt M, Zakharyan A, Durica J, Wallem A, Viktrup L. Healthcare utilization, costs, and treatment discontinuation in adults with episodic migraine initiating galcanezumab versus rimegepant: a US retrospective claims analysis. Adv Ther. 2025;42(2):918\u201334.","journal-title":"Adv Ther"},{"issue":"6","key":"872_CR46","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/ane.13599","volume":"145","author":"A L\u00f3pez-Bravo","year":"2022","unstructured":"L\u00f3pez-Bravo A, Oliveros-Cid A, Sevillano-Orte L. Treatment satisfaction with calcitonin gene-related peptide monoclonal antibodies as a new patient-reported outcome measure: a real-life experience in migraine. Acta Neurol Scand. 2022;145(6):669\u201375.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"872_CR47","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s10194-020-01177-4","volume":"21","author":"DC Buse","year":"2020","unstructured":"Buse DC, Gandhi SK, Cohen JM, Ramirez-Campos V, Cloud B, Yang R, et al. Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study. J Headache Pain. 2020;21(1):109.","journal-title":"J Headache Pain"},{"issue":"4","key":"872_CR48","doi-asserted-by":"publisher","first-page":"333102423116051","DOI":"10.1177\/03331024231160519","volume":"43","author":"LF Iannone","year":"2023","unstructured":"Iannone LF, Burgalassi A, Vigani G, Tabasso G, De Cesaris F, Chiarugi A, et al. Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: a retrospective cohort study. Cephalalgia. 2023;43(4):3331024231160519.","journal-title":"Cephalalgia"},{"issue":"2","key":"872_CR49","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40263-021-00893-y","volume":"36","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F. Long-term effectiveness of three anti-CGRP monoclonal antibodies in resistant chronic migraine patients based on the MIDAS score. CNS Drugs. 2022;36(2):191\u2013202.","journal-title":"CNS Drugs"},{"issue":"1","key":"872_CR50","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s10194-023-01585-2","volume":"24","author":"A Mu\u00f1oz-Vendrell","year":"2023","unstructured":"Mu\u00f1oz-Vendrell A, Campoy S, Caronna E, Alpuente A, Torres-Ferrus M, Nieves Castellanos C, et al. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients. J Headache Pain. 2023;24(1):63.","journal-title":"J Headache Pain"},{"key":"872_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/cells12010143","author":"AR Pavelic","year":"2022","unstructured":"Pavelic AR, W\u00f6ber C, Riederer F, Zebenholzer K. Monoclonal antibodies against calcitonin gene-related peptide for migraine prophylaxis: a systematic review of real-world data. Cells. 2022. https:\/\/doi.org\/10.3390\/cells12010143.","journal-title":"Cells"},{"issue":"1","key":"872_CR52","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s41687-021-00401-2","volume":"5","author":"WF Stewart","year":"2021","unstructured":"Stewart WF, Yan X, Pressman A, Jacobson A, Vaidya S, Chia V, et al. Combining patient reported outcomes and EHR data to understand population level treatment needs: correcting for selection bias in the migraine signature study. J Patient Rep Outcomes. 2021;5(1):132.","journal-title":"J Patient Rep Outcomes"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00872-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00872-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00872-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:06:42Z","timestamp":1768403202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00872-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["872"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00872-1","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"2 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dawn C. Buse: research support from the US Food and Drug Administration (FDA) and the National Headache Foundation; consultant, advisory board member, or honoraria or research support from AbbVie\/Allergan, Amgen, Biohaven, Eli Lilly and Company, Lundbeck, Novartis, Teva, and Theranica. Richard B. Lipton: research support from the National Institutes of Health, US FDA, and the National Headache Foundation; consultant, advisory board member, or honoraria or research support from AbbVie\/Allergan, Amgen, Axsome, Biohaven, Eli Lilly and Company, GlaxoSmithKline, Lundbeck, Merck, Novartis, Pfizer, Teva, Vector, and Vedanta Research; royalties from Wolff\u2019s Headache, 8th edition (Oxford University Press, 2009) and Informa; stock\/options in Axon, Biohaven, Cooltech, and Manistee. Robert Urman: employee and stockholder of Amgen Inc. Mark E. Bensink: was an employee of Amgen Inc. during study design and initiation and subsequently the Managing Director of Benofit Consulting, which received consulting fees from Amgen Inc. to support the interpretation of study results. Sarah C. Robinson, Shruti J. Vaidya, Alice S. Jacobson, Alexandra B. Scott, Alice R. Pressman: No conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the Sutter Health Institutional Review Board. Informed consent was collected from the survey participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Erenumab was codeveloped in partnership with Amgen Inc. and Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Additional Information"}}]}}